A phase 2 open-label safety and immunogenicity study of a meningococcal B bivalent rLP2086 vaccine in healthy adults.

[1]  Kathrin U. Jansen,et al.  Safety and Immunogenicity of a Meningococcal B Bivalent rLP2086 Vaccine in Healthy Toddlers Aged 18–36 Months: A Phase 1 Randomized-controlled Clinical Trial , 2012, The Pediatric infectious disease journal.

[2]  W. Gruber,et al.  A bivalent Neisseria meningitidis recombinant lipidated factor H binding protein vaccine in young adults: results of a randomised, controlled, dose-escalation phase 1 trial. , 2012, Vaccine.

[3]  John L. Perez,et al.  Safety, immunogenicity, and tolerability of meningococcal serogroup B bivalent recombinant lipoprotein 2086 vaccine in healthy adolescents: a randomised, single-blind, placebo-controlled, phase 2 trial. , 2012, The Lancet. Infectious diseases.

[4]  John L. Perez,et al.  A phase 1, randomized, open-label, active-controlled trial to assess the safety of a meningococcal serogroup B bivalent rLP2086 vaccine in healthy adults , 2012, Human vaccines & immunotherapeutics.

[5]  M. Ramsay,et al.  Prevalence of Serum Bactericidal Antibody to Serogroup C Neisseria meningitidis in England a Decade after Vaccine Introduction , 2012, Clinical and Vaccine Immunology.

[6]  M. Valenzuela,et al.  Immunogenicity and tolerability of a multicomponent meningococcal serogroup B (4CMenB) vaccine in healthy adolescents in Chile: a phase 2b/3 randomised, observer-blind, placebo-controlled study , 2012, The Lancet.

[7]  A. Gorringe,et al.  Bexsero: a multicomponent vaccine for prevention of meningococcal disease. , 2012, Human vaccines & immunotherapeutics.

[8]  K. Jansen,et al.  New frontiers in meningococcal vaccines , 2011, Expert review of vaccines.

[9]  J. Moon,et al.  A phase 1 study of a meningococcal native outer membrane vesicle vaccine made from a group B strain with deleted lpxL1 and synX, over-expressed factor H binding protein, two PorAs and stabilized OpcA expression. , 2011, Vaccine.

[10]  D. Toneatto,et al.  Immunogenicity and Safety of a Multicomponent Meningococcal Serogroup B Vaccine and a Quadrivalent Meningococcal CRM197 Conjugate Vaccine against Serogroups A, C, W-135, and Y in Adults Who Are at Increased Risk for Occupational Exposure to Meningococcal Isolates , 2010, Clinical and Vaccine Immunology.

[11]  M. May,et al.  Meningococcal carriage by age: a systematic review and meta-analysis. , 2010, The Lancet. Infectious diseases.

[12]  Roger French,et al.  Broad vaccine coverage predicted for a bivalent recombinant factor H binding protein based vaccine to prevent serogroup B meningococcal disease. , 2010, Vaccine.

[13]  Ellen Murphy,et al.  Sequence diversity of the factor H binding protein vaccine candidate in epidemiologically relevant strains of serogroup B Neisseria meningitidis. , 2009, The Journal of infectious diseases.

[14]  Lee H Harrison,et al.  Global epidemiology of meningococcal disease. , 2009, Vaccine.

[15]  K. Jansen,et al.  Detection of LP2086 on the cell surface of Neisseria meningitidis and its accessibility in the presence of serogroup B capsular polysaccharide. , 2009, Vaccine.

[16]  Australian Meningococcal,et al.  Annual report of the Australian Meningococcal Surveillance Programme, 2007--Amended. , 2009 .

[17]  D. Kelly,et al.  Seroprotection against serogroup C meningococcal disease in adolescents in the United Kingdom: observational study , 2008, BMJ : British Medical Journal.

[18]  David H Perlman,et al.  The Meningococcal Vaccine Candidate GNA1870 Binds the Complement Regulatory Protein Factor H and Enhances Serum Resistance , 2006, The Journal of Immunology.

[19]  R. Rappuoli,et al.  Neisseria meningitidis group B correlates of protection and assay standardization--international meeting report Emory University, Atlanta, Georgia, United States, 16-17 March 2005. , 2006, Vaccine.

[20]  M. Kieny,et al.  A review of vaccine research and development: meningococcal disease. , 2006, Vaccine.

[21]  L. McCallum,et al.  The VR2 Epitope on the PorA P1.7-2,4 Protein Is the Major Target for the Immune Response Elicited by the Strain-Specific Group B Meningococcal Vaccine MeNZB , 2006, Clinical and Vaccine Immunology.

[22]  Ross Gagliano,et al.  Review of , 2006, UBIQ.

[23]  Ying Zhang,et al.  Vaccine Potential of the Neisseria meningitidis 2086 Lipoprotein , 2004, Infection and Immunity.

[24]  G. Rougon,et al.  Clinical evaluation of a group B meningococcal N-propionylated polysaccharide conjugate vaccine in adult, male volunteers. , 2004, Vaccine.

[25]  C. Hart,et al.  Meningococcal Disease , 1974, Nursing standard (Royal College of Nursing (Great Britain) : 1987).

[26]  T. Popović,et al.  Distribution of Neisseria meningitidisSerogroup B Serosubtypes and Serotypes Circulating in the United States , 2000, Journal of Clinical Microbiology.

[27]  Robert Munro,et al.  Sequence Variation in the porA Gene of a Clone of Neisseria meningitidis during Epidemic Spread , 2000, Clinical Diagnostic Laboratory Immunology.

[28]  T. Popović,et al.  Distribution of Neisseria meningitidis Serogroup B Serosubtypes and Serotypes Circulating in the United States , 2000 .